ECOG

The ECOG talk delves into EA2174, a phase II/III trial exploring perioperative Nivolumab and Ipilimumab for esophageal cancer. With a complex design and promising progress (129 patients enrolled since 2020), the study aims to enhance surgical outcomes. The closed ANVIL (Adjuvant Nivolumab in Resected Lung Cancers) trial awaits results for adjuvant Nivolumab post-surgery. Non-surgical trials like DREM3R for mesothelioma and potential use of canakinumab in early-stage settings are also highlighted. The event underscores a comprehensive approach to cancer treatment, showcasing surgical and non-surgical advancements.